Physician profile
Kathryn T Chenault
NPI 1942290481
$531,761.07
in general payments reported to CMS, 2019-2025
48 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $51K · 2021: $63K · 2022: $74K · 2023: $105K · 2024: $69K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $205K · Consulting Fee: $26K · Food and Beverage: $13K · Travel and Lodging: $6,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,685.00 |
| Consulting Fee | $26,018.00 |
| Food and Beverage | $13,288.25 |
| Travel and Lodging | $6,194.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $293,716.42 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Biogen, INC. | $83,204.79 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $46,926.80 | 2019-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $39,397.99 | 2021-2025 | |
| Genzyme Corporation | $38,395.23 | 2019-2025 | |
| Genentech USA, INC. | $17,717.72 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $1,578.57 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $1,202.05 | 2019-2025 | Aimovig, Uplizna |
| Novartis Pharmaceuticals Corporation | $1,047.19 | 2019-2025 | |
| Abbvie INC. | $906.99 | 2021-2025 | Duopa, Ubrelvy, Botox |
| Pfizer INC. | $825.31 | 2023-2025 | |
| Celgene Corporation | $619.09 | 2020-2025 | Zeposia |
| Lilly USA, LLC | $520.38 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Amneal Pharmaceuticals LLC | $518.90 | 2019-2025 | Crexont, Lyvispah, Rytary |
| Kyowa Kirin, INC. | $481.33 | 2020-2024 | Nourianz |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Chenault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.